AU8285991A - Polymeric drug delivery system - Google Patents

Polymeric drug delivery system

Info

Publication number
AU8285991A
AU8285991A AU82859/91A AU8285991A AU8285991A AU 8285991 A AU8285991 A AU 8285991A AU 82859/91 A AU82859/91 A AU 82859/91A AU 8285991 A AU8285991 A AU 8285991A AU 8285991 A AU8285991 A AU 8285991A
Authority
AU
Australia
Prior art keywords
drug delivery
delivery system
polymeric drug
polyamines
polymeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU82859/91A
Inventor
Paul Waddell Collins
Peter Hadley Jones
Williams Eldredge Perkins
Samuel J Tremont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monsanto Co
GD Searle LLC
Original Assignee
Monsanto Co
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co, GD Searle LLC filed Critical Monsanto Co
Publication of AU8285991A publication Critical patent/AU8285991A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0206—Polyalkylene(poly)amines
    • C08G73/0213—Preparatory process
    • C08G73/0226—Quaternisation of polyalkylene(poly)amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S525/00—Synthetic resins or natural rubbers -- part of the class 520 series
    • Y10S525/923—Aminoplast having terminal ethylenic unsaturation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Phenolic Resins Or Amino Resins (AREA)

Abstract

Cross-linked controlled density polyamines which are water-insoluble and swell at pH values up to about 8 are shown. These polyamines are useful in site-specific drug delivery systems.
AU82859/91A 1990-07-26 1991-07-22 Polymeric drug delivery system Abandoned AU8285991A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55804190A 1990-07-26 1990-07-26
US558041 1990-07-26

Publications (1)

Publication Number Publication Date
AU8285991A true AU8285991A (en) 1992-02-18

Family

ID=24227945

Family Applications (2)

Application Number Title Priority Date Filing Date
AU84188/91A Abandoned AU8418891A (en) 1990-07-26 1991-07-22 Novel polyamines and method for preparation thereof
AU82859/91A Abandoned AU8285991A (en) 1990-07-26 1991-07-22 Polymeric drug delivery system

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU84188/91A Abandoned AU8418891A (en) 1990-07-26 1991-07-22 Novel polyamines and method for preparation thereof

Country Status (15)

Country Link
US (5) US5474767A (en)
EP (2) EP0540580B1 (en)
JP (2) JPH06502391A (en)
AT (2) ATE104154T1 (en)
AU (2) AU8418891A (en)
CA (2) CA2085366C (en)
DE (2) DE69118188T2 (en)
DK (2) DK0540670T3 (en)
ES (2) ES2053333T3 (en)
GR (1) GR3019804T3 (en)
IE (1) IE912630A1 (en)
NZ (1) NZ239133A (en)
PT (1) PT98442B (en)
WO (2) WO1992001730A1 (en)
ZA (1) ZA915892B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE104154T1 (en) * 1990-07-26 1994-04-15 Searle & Co DRUG RELEASING POLYMERIC SYSTEM.
DE69316861T2 (en) * 1992-12-14 1998-09-10 Monsanto Co Controlled functional density secondary polyamines and process for their preparation
US5559193A (en) * 1993-12-20 1996-09-24 Monsanto Company Controlled functional density polyamines and method for preparation thereof
US5691422A (en) * 1994-03-07 1997-11-25 Exxon Chemical Patents Inc. Saturated polyolefins having terminal aldehyde or hydroxy substituents and derivatives thereof
US5674950A (en) * 1994-03-07 1997-10-07 Exxon Chemical Patents Inc. Polymers having terminal hydroxyl aldehyde, or alkylamino substitutents and derivatives thereof
US6890524B1 (en) * 1997-04-04 2005-05-10 Monsanto Company Hydrolyzable delivery system using cross-linked polymeric resins as vehicles
US6413945B1 (en) * 1997-04-04 2002-07-02 Pharmacia Corporation Gastro-specific prodrugs
AU6590598A (en) * 1997-04-04 1998-10-30 Monsanto Company Hydrolysable delivery system using cross-linked polymeric resins as vehicles
AU6783498A (en) * 1997-04-04 1998-10-30 Monsanto Company Ph-selective delivery system using cross-linked polymeric resins as vehicles
US6030959A (en) * 1997-04-04 2000-02-29 Monsanto Company Gastro-specific prodrugs
WO2001047403A1 (en) 1999-12-28 2001-07-05 Kimberly-Clark Worldwide, Inc. Use-dependent indicator system for absorbent articles
WO2001047705A1 (en) 1999-12-28 2001-07-05 Kimberly-Clark Worldwide, Inc. Controlled release anti-microbial wipe for hard surfaces
US6315987B1 (en) * 2000-05-10 2001-11-13 Isp Investments Inc. Polymeric delivery and release systems for oral care actives
US7097181B2 (en) * 2001-11-02 2006-08-29 Outrigger, Inc. Angular handle assembly for wheeled luggage
EP1501352B1 (en) * 2001-12-14 2015-02-18 The University Of Wyoming Controlled release of oxycodone
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
JP4755495B2 (en) * 2002-12-12 2011-08-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination medicine
WO2004100926A2 (en) * 2003-05-13 2004-11-25 Medtronic, Inc. Delivery of agents using hydrolyzable leaving groups
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
KR101355422B1 (en) 2005-04-13 2014-02-06 아스션 팔마 에이/에스 Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
US8367096B2 (en) * 2005-07-19 2013-02-05 Boston Scientific Scimed, Inc. Polymers having covalently bound therapeutic agents
WO2007124131A2 (en) * 2006-04-20 2007-11-01 The University Of North Carolina At Chapel Hill Hybrid nanomaterials as multimodal imaging contrast agents
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
EP2064174B1 (en) * 2006-08-10 2016-10-26 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Preparation of (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
BRPI0807065A2 (en) * 2007-01-31 2017-03-21 Allergan Inc new biomaterials for eye drug release and a method for making and using them
US20110135571A1 (en) * 2008-02-22 2011-06-09 Wenbin Lin Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
US8945527B2 (en) * 2008-04-25 2015-02-03 The University Of North Carolina At Chapel Hill Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates
US20130203675A1 (en) 2010-09-16 2013-08-08 Joseph M. DeSimone Asymmetric biofunctional silyl monomers and particles thereof as prodrugs and delivery vehicles for pharmaceutical, chemical and biological agents
JP6049712B2 (en) 2011-07-08 2016-12-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ Metal bisphosphonate nanoparticles for anti-cancer treatment and imaging and bone disorder treatment
US10517822B2 (en) 2013-11-06 2019-12-31 The University Of Chicago Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
WO2016061256A1 (en) 2014-10-14 2016-04-21 The University Of Chicago Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
WO2018118902A1 (en) 2016-12-19 2018-06-28 The Regents Of The University Of California Dual-enzyme responsive peptides
WO2018118903A1 (en) 2016-12-19 2018-06-28 The Regents Of The University Of California Noncrushable pill formulatiions
SG10202107829YA (en) 2017-03-22 2021-08-30 Genentech Inc Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
US11826426B2 (en) 2017-08-02 2023-11-28 The University Of Chicago Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
CA3030416A1 (en) 2018-01-18 2019-07-18 Research Triangle Institute Polyamine phosphorus dendrimer materials for carbon dioxide capture

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2923662A (en) * 1957-07-11 1960-02-02 White Lab Inc Appetite depressant resin
US3383426A (en) * 1963-09-09 1968-05-14 Exxon Research Engineering Co Hydroformylation process for polymers
DE2060703A1 (en) * 1970-12-10 1972-06-22 Hoechst Ag Crystal clear polyamides
DE2524637A1 (en) * 1974-06-04 1976-01-02 Wellcome Found BIOLOGICAL REAGENTS, METHOD OF MANUFACTURING AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM
IT1044797B (en) * 1974-10-15 1980-04-21 Ferruti Paolo HIGH POLYMERS CONTAINING PROSTAGLANDINIC RADICALS PROCESS FOR THEIR PREPARATION AND USE
US4068056A (en) * 1975-03-05 1978-01-10 Exxon Research And Engineering Company Aminated polymeric additives for fuel and lubricants
US4292242A (en) * 1978-12-06 1981-09-29 Sri International Production of amines
US4356166A (en) * 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system
AU537740B2 (en) * 1979-03-21 1984-07-12 British Technology Group Limited Controlled release composition
US4296004A (en) * 1979-09-10 1981-10-20 Henkel Corporation Polycyclic polyamines
US4297481A (en) * 1980-02-22 1981-10-27 W. R. Grace & Co. Process of forming polymeric polyamine/amide
US4312965A (en) * 1980-02-22 1982-01-26 W. R. Grace & Co. Process for forming amine/amide containing polymers
US4489056A (en) * 1982-06-30 1984-12-18 Merck & Co., Inc. Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance
US4675182A (en) * 1983-02-12 1987-06-23 Bayer Aktiengesellschaft Complexes of prostaglandins
US4526936A (en) * 1983-03-18 1985-07-02 W. R. Grace & Co. Process for the preparation of polymeric amine containing products
US4558101A (en) * 1983-03-18 1985-12-10 W. R. Grace & Co. Process for the preparation of polymeric amine containing products
US4606939A (en) * 1983-06-22 1986-08-19 The Ohio State University Research Foundation Small particle formation
US4608278A (en) * 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
US4459310A (en) * 1983-06-27 1984-07-10 G.D. Searle & Co. Method for cholesterol lowering
US4503217A (en) * 1983-11-10 1985-03-05 Texaco Inc. Process for selective preparation of polymeric polyamines
US4543411A (en) * 1983-11-10 1985-09-24 Texaco Inc. Process for selective preparation of secondary and tertiary amines
US4795436A (en) * 1983-11-14 1989-01-03 Bio-Mimetics, Inc. Bioadhesive composition and method of treatment therewith
SE457505B (en) * 1984-01-10 1989-01-09 Lejus Medical Ab LAMINATED ORAL PHARMACEUTICAL COMPOSITION AND PROCEDURES FOR ITS PREPARATION
US4600578A (en) * 1984-05-11 1986-07-15 Bristol-Myers Company Method of inhibiting diarrhea
US4765973A (en) * 1984-06-06 1988-08-23 Merck & Co., Inc. Polymers containing pendant acid functionalities and labile backbone bonds
US4639366A (en) * 1984-06-06 1987-01-27 Merck & Co., Inc. Polymers containing pendant acid functionalities and labile backbone bonds
US4794199A (en) * 1984-07-05 1988-12-27 Texaco Inc. Process for synthesis of primary amines from olefins, syngas and ammonia
US4663308A (en) * 1984-07-18 1987-05-05 Medical College Of Ohio Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract
DE3686275T2 (en) * 1985-01-11 1993-03-18 Teijin Ltd PREPARED PRODUCTS WITH DELAYED RELEASE.
US4548955A (en) * 1985-02-25 1985-10-22 Sogo Pharmaceutical Company Limited Nylon capsule responding to pH
US4780319A (en) * 1985-07-08 1988-10-25 Merck & Co., Inc. Organic acids as catalysts for the erosion of polymers
US4657984A (en) * 1985-10-16 1987-04-14 Texaco Inc. Process for formation of dialkylaminomethylated internal olefin polymers
US4847250A (en) * 1985-11-29 1989-07-11 Merck & Co., Inc. Pyroglutamic acid esters used as dermal penetration enhancers for drugs
US4764364A (en) * 1986-02-25 1988-08-16 S R I International Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product
US4705898A (en) * 1986-04-04 1987-11-10 Texaco Inc. Preparation of disecondary amines from diolefins and primary amines
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
IL83715A0 (en) * 1987-08-31 1988-01-31 Yeda Res & Dev Pharmaceutical anti-protozoal compositions
DE68909982T2 (en) * 1988-03-24 1994-02-10 Taisho Pharma Co Ltd Cholesterol reducing agents.
GB8912903D0 (en) * 1989-06-05 1989-07-26 Smith Kline French Lab Compounds
GB8913699D0 (en) * 1989-06-14 1989-08-02 Smith Kline French Lab Compounds
DE3930696A1 (en) * 1989-09-14 1991-03-28 Hoechst Ag GALLENSAEUREDERIVATE, METHOD FOR THE PRODUCTION THEREOF, USE AS MEDICAMENT
YU245190A (en) * 1989-10-02 1992-07-20 Merck Patent Gesellschaft Mit Beschraenkter Haftung ELECTROOPTICAL LIQUID CRYSTALS
GB8928278D0 (en) * 1989-12-14 1990-02-21 Smith Kline French Lab Compounds
US5049625A (en) * 1990-03-08 1991-09-17 The Goodyear Tire & Rubber Company Polymeric diphenyldiamines
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
GB9010784D0 (en) * 1990-05-14 1990-07-04 Shell Int Research Process for the preparation of a secondary amine
ATE104154T1 (en) * 1990-07-26 1994-04-15 Searle & Co DRUG RELEASING POLYMERIC SYSTEM.
US5134200A (en) * 1990-10-09 1992-07-28 The Goodyear Tire & Rubber Company Polymers containing chemically bound amine antidegradants
EP0534316A1 (en) * 1991-09-21 1993-03-31 Hoechst Aktiengesellschaft Use of alkylated polyethylenimines to concentrate bile acids
AU664059B2 (en) * 1991-12-20 1995-11-02 Hoechst Aktiengesellschaft Ethylenically unsaturated bile acid derivatives, processes for their preparation and precursors
DE69316861T2 (en) * 1992-12-14 1998-09-10 Monsanto Co Controlled functional density secondary polyamines and process for their preparation

Also Published As

Publication number Publication date
EP0540670A1 (en) 1993-05-12
ZA915892B (en) 1992-09-30
US5693319A (en) 1997-12-02
GR3019804T3 (en) 1996-07-31
DK0540670T3 (en) 1996-04-29
ES2053333T3 (en) 1994-07-16
WO1992001730A1 (en) 1992-02-06
CA2085366C (en) 2001-06-12
EP0540580B1 (en) 1994-04-13
JP2611073B2 (en) 1997-05-21
JPH06502391A (en) 1994-03-17
US5474767A (en) 1995-12-12
JPH05508680A (en) 1993-12-02
DE69118188D1 (en) 1996-04-25
CA2085366A1 (en) 1992-01-27
EP0540580A1 (en) 1993-05-12
ATE135721T1 (en) 1996-04-15
WO1992001477A1 (en) 1992-02-06
US5827925A (en) 1998-10-27
EP0540670B1 (en) 1996-03-20
IE912630A1 (en) 1992-01-29
DE69101710D1 (en) 1994-05-19
CA2086527A1 (en) 1992-01-27
US5676939A (en) 1997-10-14
DK0540580T3 (en) 1994-05-16
PT98442B (en) 1999-01-29
PT98442A (en) 1992-06-30
ATE104154T1 (en) 1994-04-15
ES2084825T3 (en) 1996-05-16
NZ239133A (en) 1993-10-26
AU8418891A (en) 1992-02-18
DE69118188T2 (en) 1996-10-31
DE69101710T2 (en) 1994-08-18
US5795567A (en) 1998-08-18

Similar Documents

Publication Publication Date Title
AU8285991A (en) Polymeric drug delivery system
EP0674528A4 (en) Cyclodextrin and polymer based drug delivery system.
AU8935591A (en) Drug delivery system and method
AU7369287A (en) Sustained release formulations
AU2789792A (en) System and method for deodorant delivery in footwear
AU9617698A (en) Polymeric systems for drug delivery and uses thereof
AU641507B2 (en) Improved polymer/polyol and preformed stabilizer systems
IL117706A0 (en) Powdered drug storage and delivery system
AU7218794A (en) Internal graft prosthesis and delivery system
AU4624089A (en) Transportation dispatch and delivery tracking system
EP0736989A3 (en) Mail notification system and method
EP0475080A3 (en) Distributed messaging system and method
AU3127697A (en) Intravenous catheter and delivery system
AU6971896A (en) Stabilization systems for polymeric materials in pellet form
EP0560111A3 (en) Internodal transfer in multinode voice messaging systems
AU2770097A (en) Polymer powders redispersible in aqueous solution
GB2318366B (en) Sources used in molecular beam epitaxy
GB2227058B (en) Fuel delivery structure and fuel system.
EG20787A (en) Long acting injection suspensions and process for their preparation
AU7131894A (en) Process for determining, in tt systems, the ground resistances in the feed system and in the user's installation
AU7696596A (en) Water-dissipatable polymers and their use in aqueous systems
AU6695294A (en) Optimum water retention system for use in agricultural fields
AU3808493A (en) Biologically active N-acylprolyldipeptides having antiamnestic, antihypoxic and anorexigenic effects
GB9016071D0 (en) Molecular complexes and their uses in biological systems
GB9115270D0 (en) Molecular complexes and their uses in biological systems